Frequency Therapeutics said today that it raised a $62.0 million Series C round for the hearing loss drug it’s developing and inked a development and overseas distribution deal with Astellas Pharma that’s worth $625 million.
Woburn, Mass.-based Frequency drew a $42 million Series B early this year; including the financing announced today, a $32 million Series A and seed funding, the company says it’s put $147 million into its coffers.
Get the full story at our sister site, Drug Delivery Business News